Deguelin is a natural rotenoid extracted from several plants, including Derris trifoliate (Lour.) or Mundulea sericea (Leguminosae). It has been considered as an anti-tumor agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention (Wang et al., 2013 ). Recent reports have described multiple molecular mechanisms of deguelin function. Deguelin arrests the cell-cycle at G 2 -M phase in Raji cells derived from B lymphoblast of Burkitt's lymphoma patient (Xiong and Liu, 2013) . Interestingly, deguelin-induced cell cycle arrest seems to vary in various cancer cell lines even same origin of disease, because deguelin function has been known as G 0 -G 1 arrest in Daudi cells which is another cell line of Burkitt's lymphoma (Liu et al., 2005) . Deguelin also induces apoptosis by increasing Bax protein expression and down-regulating Bcl-2 protein expression (Bai et al., 2013) and also by suppressing PI3K/Akt signaling (Baba et al., 2015) . In this issue of EBioMedicine, Yu et al. investigated deguelin's novel anti-tumor targets (Yu et al., 2017-this issue) . Deguelin inhibited Aurora B serine/threonine kinase activity by directory docking into the ATP-binding pocket, reducing proliferation, anchorage-independent growth, and tumor development in a xenograft mouse model using esophageal squamous cell carcinoma (SCC) cell lines. Importantly, they also found that high levels of Aurora B expression in tumors were correlated with poor overall survival rate in patients with esophageal SCC. Despite the development of conventional therapies like surgery, radiation and chemotherapy, 5-year relative survival rates of esophageal SCC remain poor and esophageal SCC is associated with a high mortality rate. Therefore, Aurora B kinase is a suitable therapeutic target for esophageal SCC and deguelin is a good candidate to treat these cancer patients. Aurora B Kinase is known to be associated with 14-3-3 proteins, for example targeting Raf-1, Bcr, and Cdc25 phosphatase. Deguelin has the potential to impair 14-3-3 protein function through inhibition of Aurora B function. Deguelin can induce partial synchronization of cancer cells in the most radio-or DNA damaging agents-sensitive to G 2 -M phase, although it needs further work whether deguelin induced G 2 -M phase cell cycle arrest in various esophageal SCC cell lines, because deguelininduced cell cycle arrest seems to vary in various cancer cell lines, as mentioned above. Hoellein et al. (2011) showed that combining the epidermal growth factor (EGFR)-targeted agent cetuximab with a pan-Aurora kinase inhibitor, overcomes cetuximab resistance. In addition, inhibition of Aurora B kinase increases radiosensitivity (Clémenson et al., 2017) . Taken together, deguelin may be a double sensitizer for cetuximab and conventional chemotherapy/radiotherapy, respectively. Thus, this study provides the basis for novel combination therapy such as deguelin plus cetuximab plus conventional chemotherapy/radiotherapy in esophageal SCC.
